A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Huang, Peirong ^a   Niu, Wenquan ^b   Ni, Zhentian ^b   Wang, Renzuo ^b   Sun, Xiaodong ^a,b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC RETINOPATHY; FEMALE; HUMAN; MACULAR EDEMA; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA VEIN OCCLUSION; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84893504879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082454     Document Type: Article

References (39)

1. Orth DH, Patz A (1978) Retinal branch vein occlusion. Surv Ophthalmol 22: 357-376. (Pubitemid 8384633)
2. Branch Vein Occlusion Study Group (1986) Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 104: 34-41.
3. Shahid H, Hossain P, Amoaku WM (2006) The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 90: 627-639.
4. McAllister IL (2012) Central retinal vein occlusion: a review. Clin Experiment Ophthalmol 40: 48-58.
5. Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24: 493-519.
6. Central Vein Occlusion Study Group (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 102: 1425-1433.
7. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1124-1133 e1121.
8. Haller JA, Bandello F, Belfort R, Jr., Blumenkranz MS, Gillies M, et al. (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117: 1134-1146 e1133.
9. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, et al. (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127: 1101-1114.
10. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487. (Pubitemid 24356306)
11. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92: 905-909.
12. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, et al. (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120: 1644-1650. (Pubitemid 36401798)
13. Ciulla TA, Rosenfeld PJ (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 20: 166-174.
14. Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev: CD007325.
15. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W264.
16. Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, et al. (2007) Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology 114: 1804-1809. (Pubitemid 47483941)
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
18. Crowther M, Lim W, Crowther MA (2010) Systematic review and meta-analysis methodology. Blood 116: 3140-3146.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
20. Niu W, Qi Y, Qian Y, Gao P, Zhu D (2009) The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 32: 1060-1066.
21. Niu W, Qi Y (2011) An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 6: e24266.
22. Niu W, Qi Y (2011) Association of alpha-adducin and G-protein beta3 genetic polymorphisms with hypertension: a meta-analysis of Chinese populations. PLoS One 6: e17052.
23. Xue P, Niu WQ, Jiang ZY, Zheng MH, Fei J (2012) A meta-analysis of apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism for gallbladder stone disease. PLoS One 7: e45849.
24. Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr., et al. (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127: 374-380.
25. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, et al. (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150: 310-314.
26. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118: 2041-2049.
27. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119: 1184-1189.
28. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, et al. (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155: 429-437 e427.
29. Gutman FA (1983) Evaluation of a patient with central retinal vein occlusion. Ophthalmology 90: 481-483.
30. Fong AC, Schatz H (1993) Central retinal vein occlusion in young adults. Surv Ophthalmol 37: 393-417. (Pubitemid 23144010)
31. Lahey JM, Tunc M, Kearney J, Modlinski B, Koo H, et al. (2002) Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 109: 126-131. (Pubitemid 34027435)
32. Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126: 513-518. (Pubitemid 351549845)
33. Hayreh SS, Zimmerman MB, Podhajsky P (1994) Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 117: 429-441. (Pubitemid 24115701)
34. London NJ, Brown G (2011) Update and review of central retinal vein occlusion. Curr Opin Ophthalmol 22: 159-165.
35. Central Vein Occlusion Study Group (1995) A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology 102: 1434-1444.
36. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, et al. (2009) SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 116: 504-512.
37. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, et al. (2007) Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114: 525-536.
38. Sakamoto A, Tsujikawa A, Ota M, Yamaike N, Kotera Y, et al. (2009) Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion. Clin Experiment Ophthalmol 37: 208-216.
39. Shahsuvaryan ML, Melkonyan AK (2003) Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 13: 445-452. (Pubitemid 36807129)